1. Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma
    Shiro Suzuki et al, 2016, OncoImmunology CrossRef
  2. Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.
    Soumaya Karaki et al, 2016, Vaccines (Basel) CrossRef
  3. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
    Yu Sawada et al, 2016, OncoImmunology CrossRef
  4. An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs.
    Masatoshi Hirayama et al, 2016, Oncoimmunology CrossRef
  5. The importance of correctly timing cancer immunotherapy
    Elham Beyranvand Nejad et al, 2017, Expert Opinion on Biological Therapy CrossRef
  6. Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine
    Jeanne Galaine et al, 2015, Vaccines CrossRef
  7. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges
    Xiangjiao Meng et al, 2017, Cancer Letters CrossRef
  8. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
    Guoying Zhou et al, 2017, Gastroenterology CrossRef
  9. Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model
    Norihiro Fujinami et al, 2016, Biochemistry and Biophysics Reports CrossRef
  10. Potentiality of immunotherapy against hepatocellular carcinoma
    Nobuhiro Tsuchiya, 2015, WJG CrossRef
  11. Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine
    Toshiro Shirakawa et al, 2017, Human Vaccines & Immunotherapeutics CrossRef
  12. Checkpoint blockade in combination with cancer vaccines
    Michael A. Morse et al, 2015, Vaccine CrossRef
  13. Glypican-3-specific cytotoxic T lymphocytes induced by human leucocyte antigen-A*0201-restricted peptide effectively kill hepatocellular carcinoma cells in vitro
    Jiang-Zheng Zeng et al, 2017, Asian Pacific Journal of Tropical Medicine CrossRef
  14. null
    Ken Takahashi et al, 2018 CrossRef
  15. Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma
    Vikrant Rai et al, 2018, Mol Cell Biochem CrossRef
  16. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
    Fubo Zhou et al, 2018, Med Res Rev CrossRef
  17. Cancer immunotherapy-targeted glypican-3 or neoantigens
    Yasuhiro Shimizu et al, 2018, Cancer Sci CrossRef
  18. Proteoglycans—Biomarkers and Targets in Cancer Therapy
    Dragana Nikitovic et al, 2018, Front. Endocrinol. CrossRef
  19. Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer
    Zehong Chen et al, 2018, Cancer Sci CrossRef
  20. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences
    Chih Kit Chung et al, 2018, Journal of Controlled Release CrossRef
  21. Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy
    Gagandeep Brar et al, 2018, Therap Adv Gastroenterol CrossRef
  22. Immunotherapy: Current Status and Future Perspectives
    Charalampos S. Floudas et al, 2019, Dig Dis Sci CrossRef
  23. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma
    Yu Akazawa et al, 2019, WJMA CrossRef
  24. Next-Generation Cancer Immunotherapy Targeting Glypican-3
    Yasuhiro Shimizu et al, 2019, Front. Oncol. CrossRef
  25. Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines
    Theodore S. Nowicki et al, 2016, Pediatr Res CrossRef
  26. Vaccines for established cancer: overcoming the challenges posed by immune evasion
    Sjoerd H. van der Burg et al, 2016, Nat Rev Cancer CrossRef
  27. Immunological landscape and immunotherapy of hepatocellular carcinoma
    Jesús Prieto et al, 2015, Nat Rev Gastroenterol Hepatol CrossRef
  28. Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro.
    , 2017, Cancer Gene Ther CrossRef
  29. Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy
    Yongbing Sun et al, 2019, Asian Journal of Pharmaceutical Sciences CrossRef
  30. Role of Glypicans in Regulation of the Tumor Microenvironment and Cancer Progression
    Sukhneeraj P. Kaur et al, 2019, Biochemical Pharmacology CrossRef
  31. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
    Amit Mahipal et al, 2019, Cancers CrossRef
  32. null
    Zachary J. Brown et al, 2019 CrossRef
  33. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection
    Jiliang Feng et al, 2016, PLoS ONE CrossRef
  34. Cancer vaccines for hepatocellular carcinoma: future directions
    Franco M Buonaguro et al, 2016, Immunotherapy CrossRef
  35. Development of amino- and dimethylcarbamate-substituted resorcinol as programmed cell death-1 (PD-1) inhibitor
    An Liu et al, 2016, European Journal of Pharmaceutical Sciences CrossRef
  36. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses
    Italia Grenga et al, 2016, Clin Trans Immunol CrossRef
  37. Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial
    Yasuhiro Shimizu et al, 2019, Cancer Sci CrossRef
  38. T-cell-associated immunotherapy: a promising strategy for the treatment of hepatocellular carcinoma
    Weijie Ma et al, 2017, Immunotherapy CrossRef
  39. Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
    Jing Zhao et al, 2019, Front. Pharmacol. CrossRef
  40. Immunotherapy for hepatocellular carcinoma
    Yin Zongyi et al, 2019, Cancer Letters CrossRef
  41. Recent Advances in Immunotherapy for Hepatocellular Carcinoma
    Shigeharu Nakano et al, 2020, Cancers CrossRef
  42. Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting
    Annacarmen Petrizzo et al, 2018, Oncotarget CrossRef
  43. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies
    Rodolfo Daniel Cervantes-Villagrana et al, 2020, Sig Transduct Target Ther CrossRef
  44. Peptide vaccine as an adjuvant therapy for glypican‐3‐positive hepatocellular carcinoma induces peptide‐specific CTLs and improves long prognosis
    Masatake Taniguchi et al, 2020, Cancer Sci CrossRef
  45. An MRI-visible immunoadjuvant based on hollow Gd2O3 nanospheres for cancer immunotherapy
    Xia Li et al, 2020, Chem. Commun. CrossRef
  46. null
    Joseph Comber et al, 2020 CrossRef
  47. TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice
    Yuki Tanaka et al, 2020, Sci Rep CrossRef
  48. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.
    Benjamin Ruf et al, 2021, Cell Mol Immunol CrossRef
  49. In Silico Design of a Novel Multi-Epitope Peptide Vaccine Against Hepatocellular Carcinoma
    Fatemeh Motamedi Dehbarez et al, 2020, LDDD CrossRef
  50. Preclinical Development of a WT1 Oral Cancer Vaccine Using a Bacterial Vector to Treat Castration-Resistant Prostate Cancer
    Koichi Kitagawa et al, 2019, Mol Cancer Ther CrossRef
  51. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma.
    Julia Peña-Asensio et al, 2021, Cancers (Basel) CrossRef
  52. Nanomedicine Approach to Immunotherapy of Hepatocellular Carcinoma
    Hongbo Ni et al, 2021, j biomed nanotechnol CrossRef
  53. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
    Tai Hato et al, 2016, Immunotherapy CrossRef
  54. Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
    Kunpeng Wang et al, 2021, Front. Immunol. CrossRef
  55. In vitro evidence of oncofetal antigen and TLR-9 agonist co-delivery by alginate nanovaccines for liver cancer immunotherapy
    Mengyue Pei et al, 2022, Biomater. Sci. CrossRef
  56. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances
    Kathrine S Rallis et al, 2022, WJCO CrossRef
  57. Nanobody-based CAR T cells targeting intracellular tumor antigens
    Haixia Li et al, 2022, Biomedicine & Pharmacotherapy CrossRef
  58. Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion
    Cheng Sun et al, 2018, Nat Commun CrossRef
  59. The current status and future of PD-L1 in liver cancer
    Liyuan Hao et al, 2023, Front. Immunol. CrossRef